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ABSTRACT
Background. A sentinel lymph node (SLN) biopsy using
superparamagnetic iron oxide nanoparticles (SPIOs) as a
tracer instead of radioisotopes was first applied success-
fully in breast cancer. This study determined the feasibility
of this new technique using SPIOs and a handheld mag-
netometer to detect SLNs in prostate cancer (PC).
Methods. Enrolled 20 patients with intermediate and high-
risk PC (PSA [10 and/or Gleason score [7) in a pro-
spective study (12/2013–1/2014; DRKS00005473),
following an ethics committee approval. After transrectal
intraprostatic SPIOs injection a day earlier, patients (19/20)
underwent magnetometer-guided sentinel lymphadenec-
tomy (sPLND) and extended PLND, followed by radical
prostatectomy. One patient was not operated because of an
unrelated coagulation disorder. The ex vivo magnetic
activity of all lymph nodes (LNs) removed was measured.
The detection rate, rate of in vivo detected SLNs, and
sensitivity of sPLND was established.
Results. No adverse events attributable to SPIOs injection
were observed. Identified 126 SLNs (median 7, IQR 4–9)
and resected 334 LNs (median 17, IQR 14–19); 37 %
(7/19) of the patients had LN metastases (median 1, IQR
1–3.5). The detection rate and rate of in vivo detected
SLNs were 90 % (17/19) and 94 % (118/126) respectively.
Using sPLND, all LN metastases were detected (15/15,
sensitivity 100 %) in all patients identified with SLNs. One
LN ? patient showed no SLNs following transurethral
prostate resection.
Conclusions. This is the first study using a magnetic tracer
and magnetometer to detect SLNs in PC. Initial data
indicate that this simple, radiation-free procedure is safe,
feasible, and reliably identifies SLN and LN metastases in
most patients.
The lymph node (LN) status serves as a key predictor for
clinically localised prostate cancer (PC). In addition, reli-
able information on the presence or spread of
lymphogenous metastasizing is of great importance for
optimally directing adjuvant therapy. Pelvic lymph node
dissection (PLND) is currently the most accurate LN
staging procedure for patients with clinically localised PC.
Despite advances in radiologic imaging, none of the
available means of radiologic imaging provides an equiv-
alent level of sensitivity for the detection of LN
involvement in PC patients. Moreover, the role of PLND as
a therapeutic intervention has been the focus of renewed
interest. Several reports indicate that PLND improves
biochemical relapse-free survival, especially in patients
with minimal lymphatic dissemination.1,2
High sensitivity for identification of LN metastases
could be demonstrated for a sentinel PLND (sPLND) in PC
and other carcinomas.3–5 The procedure offers the advan-
tage of targeted removal of relatively few LNs, which also
means lower morbidity.6,7
As established for breast cancer, for example, conven-
tional use involves radioactive marking of SLNs with
99mTechnetium nanocolloid for PC patients and a handheld
gamma probe for intraoperative detection.8,9 A radioactive
tracer, however, is associated with problems. This
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procedure depends on the availability of nuclear medicine
and radio tracers, which in recent years have been prob-
lematic because of cutbacks in production. Furthermore,
the main issue is the radioactive exposure of patients and
healthcare staff. This calls for the development of new,
simpler, radiation-free, but accurate methods, for SLN
marking and intraoperative detection—especially those
that a urologist can apply independently without the com-
plicated and problematic logistics associated with nuclear
medicine.
For the aforementioned reasons, others tested a method
for identifying SLNs in breast cancer by using superpara-
magnetic iron oxide (SPIO) nanoparticles.10 It was shown
that after a subcutaneous injection, these particles flow to
the SLNs and iron deposition is seen predominantly within
sinuses and macrophages.11 This resulted in the develop-
ment of a system comprising a magnetic tracer (Sienna?)
and a handheld magnetometer (SentiMag). In two multi-
centre and multinational studies, it was possible to dem-
onstrate that for breast cancer, the new procedure is not
inferior to the established procedure of marking and
detection of SLNs using 99mTechnetium nanocolloid and a
gamma probe.12,13 This new radiation-free technology for
marking and intraoperative detection of SLNs has not yet
been evaluated for the prostate.
This is the first study in which SPIOs were injected
transrectally into the prostate to mark SLNs, and a hand-
held magnetometer was used for intraoperative
identification of SLNs. In addition to the safety and func-
tionality of the system for intraoperative detection of SLNs
following transrectal injection of Sienna?, this study also
looked at the sensitivity of the method in determining LN
metastases versus an extended PLND (ePLND).
METHODS
Study Design
The prospective, ‘‘SentiMagPro’’ pilot study applied the
concept of a novel technique for intraoperative SLN
detection, using SPIO nanoparticles and a handheld mag-
netometer in PC patients. The protocol (German Clinical
Trials Register: DRKS00005473) was approved by the
ethics committee of the Medical Chamber of Lower Sax-
ony, Germany. Twenty patients with intermediate or high-
risk PC scheduled for open radical retropubic prostatecto-
my and PLND participated in this study conducted between
3 December 2013 and 27 January 2014. Inclusion criteria
were a prostate-specific antigen (PSA) level [10.0 ng/ml
and/or a Gleason sum C7. Patients excluded were those
with known intolerance or hypersensitivity to iron or
dextran compounds, with iron overload disease, or with
pacemakers or other implantable devices in the chest wall.
Patients were informed in writing or orally, and those
recruited gave their consent in writing.
The SentiMag Technique
The SentiMag system (Endomagnetics Ltd, UK) for
marking and identifying SLNs comprises a handheld mag-
netometer, the SentiMag unit itself, and the Sienna?
magnet tracer (Endomagnetics Ltd, UK). Both are CE cer-
tified as class IIa medical devices. The size of Sienna?
particles (60 nm) is similar to that of 99mTechnetium nano-
colloid but more homogeneous. In 99mTechnetium
nanocolloid, 95 % of the particles are[80 nm in size, 4 %
lie between 80 and 100 nm, and 1 % are [100 nm.
Sienna? has comparable functional properties, because
upon injection the tracer flows just like a radio nuclide
through the lymph system and gets trapped in the SLNs
(Fig. 1). Its characteristic dark brown discolouration could
help further identify SLNs (Fig. 2).
Tracer Injection
The sentinel technique in PC differs from those in other
tumor entities. In breast cancer and malignant melanoma, a
well-directed peritumoral injection is only placed to
observe the lymphatic drainage of the tumor. In PC, which
occurs commonly multifocal, it is not known with absolute
certainty from which part of the organ the metastatic spread
originates. The currently available imaging or randomized
prostate biopsy does not allow a completely reliable
localization of all cancer foci in the prostate. Therefore, the
goal of prostate lymph scintigraphy must be the imaging of
all primary draining LNs of the prostate, under which the
SLN of cancer also exist.
In this study, a urologist injected a total of 2 ml of
Sienna? into prostates of patients 1 day before surgery,
on average 20 h before SLN detection (IQR 19–21 h),
using transrectal ultrasound guidance. Based on our own
examinations and those of others, the tracer was evenly
spread as three peripheral deposits on each side
(Fig. 3).14,15 Any adverse events, complications, or reac-
tions were noted.
Intraoperative Procedures, Histopathology
Patients underwent magnetometer (SentiMag)-guided
sPLND and ePLND, followed by radical retropubic pro-
statectomy. All cases were performed by two different high-
volume surgeons, who applied the same anatomic template
during ePLND. The ePLND template included the area
along the external iliac vessels, with the distal limit the
femoral canal. Proximally, ePLND was performed to and
including the bifurcation of the common iliac artery. All
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lymphatic fatty tissue along the internal iliac artery and
within the obturator fossa and the area dorsal of the obtu-
rator nerve was removed, as described by Weinga¨rtner
et al..16 The lateral limit consisted of the pelvic sidewall and
the medial dissection limit was defined by perivesical fat.
During sPLND, all metal retractors were removed from
the surgical field and polymer retractors (SUSI, Aescu-
lap; B. Braun Melsungen AG, Germany) were used to
avoid any kind of interference with the magnetometer
when detecting SLNs with the SentiMag probe. All SLNs
detected by the SentiMag were removed, whereby each
magnetically active LN was seen as a SLN. For surgical
reasons, LNs other than SLNs directly adjoining and
adhering to SLNs also were removed, if an in situ sepa-
ration was not possible. In this case, the LNs were ex vivo
macroscopically detected (tactile and visual) and separated
by the surgeon from each other or from the containing
fibrofatty tissue. Thereafter, an ePLND was conducted to
remove the remaining lymphatic fatty tissue from the
above-named regions. Afterwards, the LNs were macro-
scopically detected and separated by the surgeon from the
containing fibrofatty tissue, too.
The magnetic activity of all LNs also was measured
ex vivo with the SentiMag (Fig. 4). This involved sepa-
rating and registering any directly adjacent SLNs, whose
signal could not be differentiated intraoperatively. In
addition, we noted the tracer discolouration of SLNs and
measured the magnetic activity of the prostate.
Postoperatively, all LNs detected and separated by the
surgeon (SLNs and non-SLNs) were initially cut in 3-mm
transverse sections, routinely processed and completely
FIG. 2 Brown discoloured sentinel lymph node from the absorbed
iron oxide nanoparticles
FIG. 1 Examples of a sentinel lymph node and, in the centre of the
image, a 4-mm metastasis of a Gleason 8 prostate cancer after
haematoxylin and eosin (H&E) (a and c) and Perl’s Prussian blue
(b and d) staining showing the brown and blue discolouration of the
absorbed iron oxide nanoparticles in the surrounding lymphatic tissue
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embedded in paraffin, whereas 4–5-lm-thick sections were
stained with hematoxylin-eosin.
Analysis
A successful procedure was defined as an intraoperative
detection of at least one SLN by the SentiMag
magnetometer. This served to determine the detection rate
(number of patients with detected SLNs/total number
operated). Also computed was the rate of SLNs correctly
detected in vivo by the SentiMag (number of SLNs
detected in vivo/number of SLNs detected ex vivo), along
with the sensitivity of sPLND (number of positive SLNs/
total number of positive LNs).
RESULTS
Table 1 lists the summary of patient characteristics.
None of the 20 patients exhibited adverse events attribut-
able to the injection of Sienna?. One patient could not be
operated because of a newly found, unrelated coagulation
disorder that was not known during the preliminary
examination. A total of 126 SLNs (median 7, IQR 4–9)
were identified, and in all 334 LNs (median 17, IQR 14–19)
were removed. LN metastases were found in 7 of the 19
patients operated (37 %), with a median of one positive LN
(IQR 1–3.5). Of the LN metastases, 25 % each were local-
ised in the area of the obturator fossa and hypogastric region
and 50 % in region of the external iliac vessels.
SLNs were detected in 17 of the 19 patients operated
(median 7, IQR 5–9), which equals a detection rate of
90 %. SLNs were not found in either one LN positive
patient after transurethral prostate resection, or in a case of
long-term transurethral catheter with a relapsing infection.
SentiMag correctly detected 118 (94 %) of SLNs in vivo
from among 126 magnetically active LNs identified
ex vivo. In one case, a SLN could not be detected in vivo
because of an existing hip endoprosthesis. The other
(n = 7) undetected SLNs lay mostly close to the prostate.
In all patients with SLNs and positive LNs (6/6),
metastases (15/15) were exclusively detected in SLNs
identified in vivo by SentiMag, which means a 100 %
sensitivity of magnetometer-guided sPLND. Moreover, a
LN metastasis without SLN identification was found in one
patient after transurethral prostate resection. See Table 1
for details by patients of the number of LNs and LN
metastases removed.
All prostates were magnetically active, with maximum
activity measured between 4,143 and [9,999 units. The
SLNs showed a median magnetic activity level of 338 units
(IQR 127–950), whereby the activity of positive SLNs was
a median of 443 units (IQR 127–950). Only 18.3 %
(23/126) of the SLNs exhibited macroscopically clearly
visible brown discolouration.
DISCUSSION
Based on several thousand patients, radioguided sPLND
using 99mTechnetium nanocolloid has been found to be
FIG. 4 Ex vivo magnetic activity of a sentinel lymph node measured







FIG. 3 Schematic illustration of Sienna? injection. The magnetic
tracer (total of 2 ml) were injected transrectally in three deposits each
on both sides of the prostate’s peripheral zone, using ultrasound
guidance
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highly sensitive for identifying LN metastases in PC
patients.3,4,17 It was possible to demonstrate that for a
sPLND, the rate of LN involvement was higher in a sen-
tinel cohort than was expected from the European
Association of Urology guideline nomogram.17 In the
SentiMag study, the rate of LN positive patients (37 %) is
comparatively high, despite the intermediate and high-risk
profile of patients. The possibility of an ePLND over-
looking a part of the LN metastases, possibly in the
presacral region, is overcome by being able to detect it
through the sPLND. Reportedly, Joniau et al. 18 did not
detect 13 % of metastatic LNs by applying only conven-
tional standard ePLND.
Moreover, the targeted sentinel procedure has the
advantage, versus an ePLND, that relatively few LNs must
be removed. This consequently minimizes the intervention
and significantly reduces the histopathology. A lower
number of LNs can be explored more extensively. For
example, more small or micrometastases can be detected
by increasing the number of sections.
In the meantime, efforts are underway on targeted
removal of LNs in combination with laparoscopic or robot-
assisted radical prostatectomies, in order to lower the
extensive effort associated with an ePLND.19–21
The morbidity of PLND is still under debate. However,
in this context it should be considered that the complica-
tions of PLND increase significantly with the number of
dissected LNs, as shown previously by different studies.6
In a study of our working group, it was shown that the total
and lymphatic complications increased significantly if
more than15 LNs have been dissected, and that sPLND,
despite the dissection of SLNs in regions with difficult
accessibility (e.g., presacral), has a low morbidity.7 Many
of these complications are not serious, but in some cases,
considerable therapeutic additional effort is required.
Nevertheless, the pros of conventional radioactive
marking with 99mTechnetium nanocolloid also come with
some cons. For instance, the technology is subject to strict
regulations and problems involving the presence of nuclear
medicine. Also, there are concerns regarding the availability


















1 67 16.59 T1c 7 (4 ? 3) pT3b N1 7 (3 ? 4) 11 10 5 5
2 61 17.9 T2b 7 (3 ? 4) pT3b N0 7 (4 ? 3) 16 3 0 0
3 63 1.31 T2c 7 (4 ? 3) pT3b N0 7 (4 ? 3) 23 14 0 0
4 63 50.5 T2b 7 (3 ? 4) pT2c N0 7 (4 ? 3) 14 5 0 0
5 65 4.97 T1c 7 (3 ? 4) pT2c N0 7 (3 ? 4) 15 0 0 0
6 53 9.16 T1c 7 (3 ? 4) pT2a N0 7 (3 ? 4) 13 5 0 0
7 66 11.31 T1c 7 (3 ? 4) pT3a N1 7 (3 ? 4) 11 7 1 1
8 66 7.9 T1c 7 (3 ? 4) pT2c N0 7 (3 ? 4) 14 5 0 0
9 55 5.86 T2b 7 (4 ? 3) pT2c N0 7 (4 ? 4) 17 4 0 0
10 63 6.12 T1c 7 (3 ? 4) pT2c N0 7 (3 ? 4) 17 9 0 0
11* 75 12.2 T2c 7 (3 ? 3) pT3b N1 7 (4 ? 3) 18 0 1 0
12 67 19.63 T1c 6 (3 ? 3) pT2a N0 7 (3 ? 4) 19 7 0 0
13 64 12.9 T1c 6 (3 ? 3) pT2c N0 7 (3 ? 4) 19 12 0 0
14 63 48.68 T3a 7 (4 ? 3) pT4 N1 9 (4 ? 5) 32 2 1 1
15 68 12.1 T2b 7 (4 ? 3) pT3b N1 9 (4 ? 5) 15 12 5 5
16 78 4.88 T2c 8 (4 ? 4) pT3b N1 8 (4 ? 4) 19 7 2 2
17$ 72 14.5 T2a 7 (4 ? 3) n/a n/a n/a n/a n/a n/a n/a
18 68 29.18 T2c 10 (5 ? 5) pT3b N1 9 (4 ? 5) 23 9 1 1
19 72 30.97 T2c 7 (3 ? 4) pT3a N0 7 (4 ? 3) 24 8 0 0
20 53 13.98 T1c 7 (3 ? 4) pT2c N0 7 (3 ? 4) 14 7 0 0
Median 65.5 12.55 17 7 1§ 1.5§
PSA prostate specific antigen; c clinical values; p pathological values; LN lymph node; SLN sentinel lymph node
* This patient had undergone a transurethral prostate resection in the past
$ This patient did not undergo prostatectomy and lymphadenectomy
§ Patients with lymph node metastases
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of 99mTechnetium nanocolloid, because its parent isotope,
99mMo, is produced in only a few reactors worldwide. These
have not been fully operational in recent years, which has led
to big bottlenecks and interruption of supplies. Worthy of
mention are the problems of radiation exposure of patients
and healthcare staff, as well as inherent problems with the
production and disposal of radioactive materials.
For the above reasons, this is the first study that concen-
trated on a new, nonradioactive, purely magnetic technology
using handheld magnetometers for SLN marking and intra-
operative detection in PC patients. Earlier, it was possible to
demonstrate that, for breast cancer, this Sienna?/Sent-
iMag system was not inferior to the established procedure
of marking with 99mTechnetium nanocolloid.12,13
In this prospective pilot study, we were able to show, for
the first time, that magnetic marking and intraoperative
detection of SLNs and the Sienna?/SentiMag system
are suited for the prostate. Although this feasibility study
was applied for the first time ever to the prostate, the
detection rate of 90 % was comparably high. The first
examinations of breast cancer detected only 77 % of the
SLNs following marking with SPIOs.22 The multi-centre
trials of breast cancer came up with a detection rate of 94
and 98 %.12,13 For the prostate, a meta-analysis of
99mTechnetium nanocolloid guided sPLND showed a
pooled detection rate of 94 %.4 In contrast, Manny et al.
observed a detection rate of only 76 % with indocyanine
green (ICG) fluorescence marking, whereas the in vivo
detection rate of SLNs with the SentiMag probe was high
(94 %).21 For example, despite application of a hybrid
tracer (ICG-99mTechnetium nanocolloid), van der Poel
et al. 20 could not detect 15 % of the SLNs intraoperative.
In the SentiMagPro study More SLNs (median 7) were
detected (median of 2 SLNs) than in our studies with
99mTechnetium nanocolloid (median 5–6 SLNs) or by
others with hybrid tracers.9,17,20
In the SentiMagPro study, we were able to identify
100 % of the LN metastases in patients with SLNs detected
by magnetometer guided sPLND. One patient, who had
undergone transurethral prostate resection and in whom no
SLN was detectable, a LN metastasis was resected with
ePLND. In a meta-analysis, Sadeghi et al.4 found the
pooled sensitivity of radio-guided sPLND to be 94 %.
Beyond the high detection reliability of the SentiMag
system, one should weigh the fact that the radiation-free,
magnetometer-guided sPLND procedure is simple and can
be performed alone by a urologist. In contrast, in recent
years alternatives to the deployment of 99mTechnetium
nanocolloid for the prostate have been tested in combina-
tion with laparoscopy or robotic radical prostatectomy
fluorescence (ICG)-based or coupled procedures
(ICG-99mTechnetium nanocolloid) that are either quite
extensive or again involve radioactivity.19,21,23 Moreover,
these techniques are principally restricted by the limited
tissue penetration of near-infrared fluorescence signals
(\1 cm) and the functional properties of the free ICG.24,25
Functionally, ICG is a rapidly clearing lymphatic perfu-
sions marker, which does not remain in the SLNs like the
radiocolloid and/or is not absorbed there like the latter by
macrophages.26 Furthermore, the fluorescence approach for
open operations means a much more complex effort and
higher costs.24,27,28
Magnetic tracers have another big advantage over other
techniques because of the ability to visualise them through
magnetic resonance imaging (MRI). Although Sienna? itself
has not been approved as a contrast agent, its properties are
comparable with those of other SPIOs deployed as negative
contrast agents in MRI for identifying (S)LN metastases.29,30
In addition to limitations related to magnetism, such as
the presence of endoprostheses, this new technique also has
the same principal limitations of the sentinel method. As
with radioactive marking, tissue changes resulting from a
transurethral prostate resection or subsided inflammations
(as was the situation for both SLN negative patients in this
study) could hinder the flow of lymph fluids from the
prostate and thereby the SLN marking.3,8,9
In view of the aforementioned issues, and because an eP-
LND is required in such cases without identification of SLN
metastases, these initial findings suggest deployment of the
Sienna?/SentiMag system or a magnetometer-guided
sPLND for prostate carcinomas. This is further underscored
by the fact that this procedure offers a level of confidence for
identification of LN metastases equivalent to that of conven-
tional radioactive marking. More work is needed to confirm
the highly promising findings of this feasibility study and to
answer open questions, for example, through direct compar-
ison with conventional radioactive marking or other tracers.
CONCLUSIONS
This prospective, clinical, pilot study delivered the first
convincing results on magnetic marking and magnetome-
ter-guided sPLND in PC. The procedure appears to be safe,
can be performed easily and alone by a urologist, and has
the advantage of no radioactive elements. Should these
initial findings including the technique’s high sensitivity
for identifying metastases be validated in a larger or mul-
ticentre study, the new technique could have the potential
to achieve targeted improvements in LN surgery in PC—at
a comparably low level of effort.
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